Evidence map›Paper›PMID 36234449›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Polyhydroxy Fullerenes Enhance Antibacterial and Electrocatalytic Activity of Silver Nanoparticles.

Luis Palomino, Danae A Chipoco Haro, Miguel Gakiya-Teruya, Feng Zhou, Adolfo La Rosa-Toro, Vijay Krishna, Juan Carlos F Rodriguez-Reyes

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luis PalominoLaboratory of Nanoscience and Applications-NASCA, Universidad de Ingenieria y Tecnologia-UTEC, 165 Medrano Silva, Barranco, Lima 15063, Peru.ORCID 0000-0002-3992-3123
Danae A Chipoco HaroLaboratory of Nanoscience and Applications-NASCA, Universidad de Ingenieria y Tecnologia-UTEC, 165 Medrano Silva, Barranco, Lima 15063, Peru.ORCID 0000-0002-5095-3446
Miguel Gakiya-TeruyaLaboratory of Nanoscience and Applications-NASCA, Universidad de Ingenieria y Tecnologia-UTEC, 165 Medrano Silva, Barranco, Lima 15063, Peru.
Feng ZhouDepartment of Biomedical Engineering, Cleveland Clinic, Lerner Research Institute, Cleveland, OH 44106, USA.ORCID 0000-0001-6014-6894
Adolfo La Rosa-ToroLaboratorio de Investigacion de Electroquimica Aplicada, Facultad de Ciencias, Universidad Nacional de Ingenieria, Av. Tupac Amaru 210, Rimac, Lima 15333, Peru.ORCID 0000-0001-8143-9936
Vijay KrishnaDepartment of Biomedical Engineering, Cleveland Clinic, Lerner Research Institute, Cleveland, OH 44106, USA.
Juan Carlos F Rodriguez-ReyesLaboratory of Nanoscience and Applications-NASCA, Universidad de Ingenieria y Tecnologia-UTEC, 165 Medrano Silva, Barranco, Lima 15063, Peru.ORCID 0000-0003-2271-4613

Funding

UTEC Faculty grants 819051UTEC Faculty Grants 819003
6 · The paper itself

Abstract

Silver nanoparticles (AgNPs) are known and widely used for their antibacterial properties. However, the ever-increasing resistance of microorganisms compels the design of novel nanomaterials which are able to surpass their capabilities. Herein, we synthesized silver nanoparticles using, for the first time, polyhydroxy fullerene (PHF) as a reducing and capping agent, through a one-pot synthesis method. The resulting nanoparticles (PHF-AgNPs) were compared to AgNPs that were synthesized using sodium citrate (citrate-AgNPs). They were characterized using high-resolution transmission electron microscopy (HR-TEM), dynamic light scattering, and UV-visible spectroscopy. Our results showed that PHF-AgNPs have a smaller size and a narrower size distribution than citrate-AgNPs, which suggests that PHF may be a better capping agent than citrate. Antibacterial assays using

Indexed as

antibacterial activityone-pot synthesisoxygen evolution reactionoxygen reduction reactionpolyhydroxy fullerenesilver nanoparticles

Identifiers

PMID36234449
PMCPMC9565599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.